Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ASC11/Ritonavir in Healthy Subjects
NCT05718518Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC11 in coronavirus disease 2019 (COVID-19), sponsored by Ascletis Pharma Inc. Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 14 days. Started Jan 2023; status: completed.
02
Drugs
ASC11
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05718518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718518.